What happened with CYTK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cytokinetics’ first commercial medicine, MYQORZO (aficamten), treats adults with symptomatic obstructive hypertrophic cardiomyopathy. It reduces heart-muscle contraction by inhibiting a protein involved in generating force. The company sells it directly in the United States through its own sales and distribution network, focusing on specialist cardiologists and treatment centers. Commercial drug sales have only recently begun; its other drug candidates remain in clinical testing.
Before MYQORZO’s launch, revenue came mainly from licensing and collaboration payments, with Bayer the largest contributor and Sanofi another important source. Sanofi holds aficamten rights in China and Taiwan, while Bayer holds rights in Japan. These partners pay Cytokinetics for agreed development and commercial milestones and owe royalties on regional sales, making that income dependent on their progress.
MYQORZO sales depend on physicians prescribing it and insurers and government payors covering treatment. Its U.S. approval requires a safety-risk management program because the drug can cause heart failure through reduced pumping function. Cytokinetics has no drug-manufacturing facilities and relies on single-source contractors for key supply stages. It also continues to need outside capital to support development and commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cytokinetics’ results hinge on MYQORZO uptake and expansion into new patient groups; Bayer, absent from this list, holds the exclusive Japanese aficamten license and owes milestones and sales royalties.
Bristol Myers Squibb’s Camzyos competes directly with Cytokinetics’ MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy, making Camzyos sales a gauge of the competition MYQORZO faces. Both companies sell medicines for this patient group; differences in their labels and required safety monitoring matter to Cytokinetics’ competitive position.
Edgewise Therapeutics is developing EDG-7500 for HCM patients served by Cytokinetics’ MYQORZO, while its EDG-15400 could compete with ulacamten in heart failure with preserved ejection fraction. Edgewise had generated no revenue through December 31, 2025, so watch these candidates’ clinical progress rather than drug sales for signs of future competition.
Braveheart Bio’s BHB-1893 could challenge Cytokinetics’ aficamten in both obstructive and non-obstructive HCM, but remains a drug in development rather than a commercial rival. Braveheart depends on this sole candidate and planned a global Phase 3 obstructive HCM trial in 2026, making that trial’s progress the news to watch.
Lexicon Pharmaceuticals’ Phase 3 study of sotagliflozin in obstructive and non-obstructive HCM overlaps both MYQORZO’s market and Cytokinetics’ opportunity to expand aficamten use. Lexicon earns revenue from drug sales, collaborations and licenses, but this HCM trial—not its overall revenue—is the concrete development to watch for potential competition.
Royalty Pharma funds Cytokinetics in exchange for a share of medicine sales, so commercial success brings receipts to both businesses while Cytokinetics gives up part of its sales revenue. Its affiliate receives 4.5% of worldwide annual aficamten net sales up to $5 billion and 1% above that; additional ulacamten funding depends on AMBER-HFpEF results and the affiliate’s decision.
Cytokinetics relies on Sanofi to develop and sell licensed aficamten products, including MYQORZO, in China and Taiwan, receiving milestones and a share of sales in return. Watch Sanofi’s MYQORZO rollout in China, though Cytokinetics expected its 2026 royalty revenue to be immaterial during initial commercialization.
Tenaya Therapeutics’ TN-201 could compete for the MYBPC3-associated subset of HCM patients within Cytokinetics’ aficamten market. Tenaya is testing this gene therapy in Phase 1b/2 and had no approved products or revenue through December 31, 2025, so its trial results—not sales—are the signal to watch.
Kardigan’s danicamtiv targets genetic dilated cardiomyopathy, overlapping the weak-heart-contraction opportunity Cytokinetics is pursuing with omecamtiv mecarbil rather than MYQORZO’s market. Kardigan has no product sales in the reported period; progress in its Phase 2b/3 KINSHIP-DCM trial is the concrete signal to watch for this potential heart-failure rival.
Fed Interest Rate Decision
Fed rate decisions shape the interest Cytokinetics earns on its $1.2 billion in cash, cash equivalents and marketable securities, a source of funding for its drug development and commercialization.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could lift earnings on Cytokinetics’ cash and investments, adding to funding for research and development and MYQORZO commercialization; higher rates could also make new borrowing more costly.
If it comes in below expectations
Lower rates could reduce earnings on Cytokinetics’ cash and investments, leaving less interest income to support research and development and MYQORZO commercialization; new borrowing could become less costly.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show how Camzyos is selling to adults with symptomatic obstructive HCM, the same patient group Cytokinetics targets with MYQORZO.
Read Camzyos sales alongside Bristol Myers Squibb’s comments on demand and treatment requirements. Stronger sales would show an established rival drawing demand from the shared patient group, which MYQORZO must also reach; weaker sales could reflect slower uptake or access hurdles, not a shift to MYQORZO. Their labels and safety-monitoring requirements differ, so sales alone cannot establish which drug patients prefer.
Sanofi earningsSNY
Sanofi is responsible for commercializing licensed aficamten products in China; its report may show whether the MYQORZO rollout is building a future source of sales-linked royalties for Cytokinetics.
Look for Sanofi to discuss MYQORZO’s rollout or sales in China specifically; its company-wide results are not a measure of this drug’s performance. Launch progress and sales would show the partner is building a path to future sales-linked royalties for Cytokinetics; a slow rollout would delay that opportunity. Cytokinetics expected royalties to be immaterial during initial commercialization in 2026, so this is mainly a read on market access taking shape, not near-term revenue size.
Cytokinetics Inc. earningsThis company
Cytokinetics is selling MYQORZO directly in the U.S.; this report will show whether its focused cardiology launch is turning into product sales.
Separate MYQORZO product sales from collaboration, license and milestone revenue, then weigh sales against commercialization spending and cash used in operations. Rising product sales without costs growing faster would show the launch is starting to build a commercial revenue stream; little sales alongside faster-rising costs would show approval has not yet become meaningful commercial traction.
